Press Releases
Hogan Lovells advises Medicines Development for Global Health in the Sale of its Priority Review Voucher
14 May 2019
Erin J. Howell
Senior AssociateNew York
Email erin.howell@hoganlovells.com
Phone +1 212 918 3634
Fax +1 212 918 3100
Practice groupCorporate
Erin Howell knows that a valuable adviser needs both breadth and depth of knowledge. That's her key to advising clients across a broad range of industries on their most important corporate transactions, while maintaining a particular focus on key industries. From life sciences to life insurance, Erin has counseled clients on a variety of business, corporate, and regulatory matters.
Erin focuses on U.S. and international mergers and acquisitions, internal reorganizations, and asset purchase and sale transactions – including pharmaceutical products and blocks of insurance business. Erin has represented clients in industries as varied as financial services, pharmaceuticals and life sciences, textiles, transportation, and health services. Within the insurance industry, she brings a decade of experience dealing with complex reinsurance, transactional, and regulatory matters, including M&A, renewal rights, shell acquisitions, and regulatory issues for insurance underwriters, producers, and reinsurers.
Awards and recognitions
2010
Legal Aid Society Recognition Award
Education and admissions
Education
J.D., University of California, Berkeley School of Law, 2008
B.A., Michigan State University, summa cum laude, 2003
Bar admissions and qualifications
New York
Representative experience
Medicines Development for Global Health on the sale of its Priority Review Voucher.
Novartis in connection with a strategic collaboration with Cellular Biomedicine Group, Inc. to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
Novartis on its licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates.
Celgene on the entry into a strategic collaboration and licensing agreement with Kyn Therapeutics with an $80 million upfront payment.
Helsinn Healthcare SA in connection with the acquisition of the worldwide rights to Valchlor©/Ledaga© from Actelion Pharmaceuticals, Ltd.
Kiadis, a clinical stage biopharmaceutical company, on its acquisition of US-based CytoSen Therapeutics, Inc.
Elastagen Pty Ltd in relation to its sale to Allergan plc for up to US$260m.
A leading global life sciences company on its minority investment in a clinical lab, with an option to acquire.
Representation of a Bermuda-based reinsurance company in acquiring U.S. insurance companies.
Representation of a global transportation company in a strategic investment in a small business.
Regular representation of international property/casualty insurer in preparation of Holding Company Act filings.
Representation of publicly held insurer in divesting non-core insurance business.
Latest thinking and events
Published Works
Global M&A Trumps Populism and Politics Bloomberg Law Mergers & Acquisitions Law Report
14 August 2017
